Novo Nordisk challenges Pfizer's $47.50 per share deal for Metsera with a $6.5B bid, offering $56.50 per share in cash up front plus potential milestones.
Novo Nordisk challenges Pfizer's $47.50 per share deal for Metsera with a $6.5B bid, offering $56.50 per share in cash up front plus potential milestones.